Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Tissue-based immune monitoring I: tumor core needle biopsies allow in-depth interrogation of the tumor microenvironment.

Hagemann AR, Cadungog M, Hagemann IS, Hammond R, Adams SF, Chu CS, Rubin SC, Zhang L, Addya K, Birrer MJ, Gimotty PA, Coukos G.

Cancer Biol Ther. 2011 Aug 15;12(4):357-66. Epub 2011 Aug 15.

2.

Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma.

Hagemann AR, Hagemann IS, Cadungog M, Hwang WT, Patel P, Lal P, Hammond R, Gimotty PA, Chu CS, Rubin SC, Birrer MJ, Powell DJ Jr, Feldman MD, Coukos G.

Cancer Biol Ther. 2011 Aug 15;12(4):367-77. Epub 2011 Aug 15.

3.

The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer.

Preston CC, Maurer MJ, Oberg AL, Visscher DW, Kalli KR, Hartmann LC, Goode EL, Knutson KL.

PLoS One. 2013 Nov 14;8(11):e80063. doi: 10.1371/journal.pone.0080063. eCollection 2013.

4.

Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry: robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP.

Coutinho R, Clear AJ, Mazzola E, Owen A, Greaves P, Wilson A, Matthews J, Lee A, Alvarez R, da Silva MG, Cabeçadas J, Neuberg D, Calaminici M, Gribben JG.

Haematologica. 2015 Mar;100(3):363-9. doi: 10.3324/haematol.2014.110189. Epub 2014 Nov 25.

5.

The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.

Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Gastl G, Gunsilius E, Marth C.

Clin Cancer Res. 2005 Dec 1;11(23):8326-31.

6.

Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies.

Pisa P, Halapi E, Pisa EK, Gerdin E, Hising C, Bucht A, Gerdin B, Kiessling R.

Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7708-12.

7.

Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer.

García-Martínez E, Gil GL, Benito AC, González-Billalabeitia E, Conesa MA, García García T, García-Garre E, Vicente V, Ayala de la Peña F.

Breast Cancer Res. 2014 Nov 29;16(6):488. doi: 10.1186/s13058-014-0488-5.

8.

Double-negative (CD4- CD8-) T cells from adult T-cell leukemia patients also have poor expression of the T-cell receptor alpha beta/CD3 complex.

Suzushima H, Asou N, Nishimura S, Nishikawa K, Wang JX, Okubo T, Naito M, Hattori T, Takatsuki K.

Blood. 1993 Feb 15;81(4):1032-9.

9.

All infiltrating T-lymphocytes in Hodgkin's disease express immunohistochemically detectable T-cell receptor zeta-chains in situ.

Dukers DF, Oudejans JJ, Jaspars EH, Gras M, Vos W, Middeldorp JM, Meijer CJ, Bloemena E.

Histopathology. 2000 Jun;36(6):544-50.

PMID:
10849097
10.

Change in expression pattern of TCR-CD3 complex in patients with multiple myeloma.

Li Y, Chen S, Yang L, Chen S, Lin C, Wang L, Lu Y, Geng S, Du X, Schmidt CA.

Hematology. 2011 May;16(3):143-50. doi: 10.1179/102453311X12953015767491.

PMID:
21669053
11.

Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care.

Tebbit CL, Zhai J, Untch BR, Ellis MJ, Dressman HK, Bentley RC, Baker JA, Marcom PK, Nevins JR, Marks JR, Olson JA Jr.

Breast Cancer Res Treat. 2009 Dec;118(3):635-43. doi: 10.1007/s10549-008-0301-1. Epub 2009 Feb 18.

12.

Gene expression signature with independent prognostic significance in epithelial ovarian cancer.

Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, Libermann TA, Cannistra SA.

J Clin Oncol. 2004 Dec 1;22(23):4700-10. Epub 2004 Oct 25. Erratum in: J Clin Oncol. 2005 Jan 1;23(1):248.

PMID:
15505275
13.

Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer.

Garg M, Chaurasiya D, Rana R, Jagadish N, Kanojia D, Dudha N, Kamran N, Salhan S, Bhatnagar A, Suri S, Gupta A, Suri A.

Clin Cancer Res. 2007 Mar 1;13(5):1421-8.

15.

Microarray expression identification of differentially expressed genes in serous epithelial ovarian cancer compared with bulk normal ovarian tissue and ovarian surface scrapings.

Grisaru D, Hauspy J, Prasad M, Albert M, Murphy KJ, Covens A, Macgregor PF, Rosen B.

Oncol Rep. 2007 Dec;18(6):1347-56.

PMID:
17982616
16.

Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.

Shigemasa K, Tian X, Gu L, Tanimoto H, Underwood LJ, O'Brien TJ, Ohama K.

Oncol Rep. 2004 Jun;11(6):1153-9.

PMID:
15138549
17.

Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression.

Motamed-Khorasani A, Jurisica I, Letarte M, Shaw PA, Parkes RK, Zhang X, Evangelou A, Rosen B, Murphy KJ, Brown TJ.

Oncogene. 2007 Jan 11;26(2):198-214. Epub 2006 Jul 10.

PMID:
16832351
18.

Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer.

Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ, Lockhart DJ, Burger RA, Hampton GM.

Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1176-81.

19.

Changes in gene expression in liver tissue from patients with fulminant hepatitis E.

Naik A, Goel A, Agrawal V, Sarangi AN, Chhavi N, Singh V, Jameel S, Aggarwal R.

World J Gastroenterol. 2015 Jul 14;21(26):8032-42. doi: 10.3748/wjg.v21.i26.8032.

20.

Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis.

Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I, Smith D, Hartmann L, Fishman D, Berchuck A, Schmandt R, Whitaker R, Gershenson DM, Mills GB, Bast RC Jr.

Clin Cancer Res. 2004 May 15;10(10):3291-300.

Supplemental Content

Support Center